Modeling of Parkinson’s Disease Progression and Implications for Detection of Disease Modification in Treatment Trials
Journal of Parkinson’s Disease · 03.09.2024 · 14 (6) · 1225-1235
DOI: 10.3233/jpd-230446 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Parkinson’s Disease, online erschienen am 20.07.2024. Verfasst von Benjamin Ribba und 9 weiteren Autor:innen. Beteiligte Einrichtung: Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland. Hauptthemen laut MEDLINE: Parkinson Disease, Disease Progression. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Objectively measuring Parkinson’s disease (PD) signs and symptoms over time is critical for the successful development of treatments aimed at halting the disease progression of people with PD.
Objective
To create a clinical trial simulation tool that characterizes the natural history of PD progression and enables a data-driven design of randomized controlled studies testing potential disease-modifying treatments (DMT) in early-stage PD.
Methods
Data from the Parkinson’s Progression Markers Initiative (PPMI) were analyzed with nonlinear mixed-effect modeling techniques to characterize the progression of MDS-UPDRS part I (non-motor aspects of experiences of daily living), part II (motor aspects of experiences of daily living), and part III (motor signs). A clinical trial simulation tool was built from these disease models and used to predict probability of success as a function of trial design.
Results
MDS-UPDRS part III progresses approximately 3 times faster than MDS-UPDRS part II and I, with an increase of 3 versus 1 points/year. Higher amounts of symptomatic therapy is associated with slower progression of MDS-UPDRS part II and III. The modeling framework predicts that a DMT effect on MDS-UPDRS part III could precede effect on part II by approximately 2 to 3 years.
Conclusions
Our clinical trial simulation tool predicted that in a two-year randomized controlled trial, MDS-UPDRS part III could be used to evaluate a potential novel DMT, while part II would require longer trials of a minimum duration of 3 to 5 years underscoring the need for innovative trial design approaches including novel patient-centric measures.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
- Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
- Institute for Neurodegenerative Disorders, New Haven, CT, USA.
- Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
- Roche Product Development, F. Hoffmann La Roche Ltd., Basel, Switzerland.
- University of Exeter Medical School, London, UK.
Zitieren
APA
Ribba, B., Simuni, T., Marek, K., Siderowf, A., Diack, C., Pierrillas, P. B., Monnet, A., Ricci, B., Nikolcheva, T., & Pagano, G. (2024). Modeling of Parkinson’s Disease Progression and Implications for Detection of Disease Modification in Treatment Trials. Journal of Parkinson’s Disease, 14(6), 1225-1235. https://doi.org/10.3233/jpd-230446
Vancouver
Ribba B, Simuni T, Marek K, Siderowf A, Diack C, Pierrillas PB, et al. Modeling of Parkinson’s Disease Progression and Implications for Detection of Disease Modification in Treatment Trials. Journal of Parkinson’s Disease. 2024;14(6):1225-1235. doi:10.3233/jpd-230446
BibTeX
@article{Ribba2024,
author = {Ribba, Benjamin and Simuni, Tanya and Marek, Kenneth and Siderowf, Andrew and Diack, Cheikh and Pierrillas, Philippe Bernard and Monnet, Annabelle and Ricci, Benedicte and Nikolcheva, Tania and Pagano, Gennaro},
title = {Modeling of Parkinson’s Disease Progression and Implications for Detection of Disease Modification in Treatment Trials},
journal = {Journal of Parkinson’s Disease},
year = {2024},
volume = {14},
number = {6},
pages = {1225--1235},
doi = {10.3233/jpd-230446}
}
EUVIMED